September 26, 2018
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the launch of Immune Response Template (IRT) online. IRT is a QSP platform of human immune system and a tool for development of custom QSP models related to immune response.
Immune Response Template is an innovative tool allowing users to select all or any reactions and species from IRT Core Model, QSP model of immune response in humans, and download it.
Previous version of IRT has been successfully used for development of models in various therapeutic areas: autoimmune diseases (SLE), respiratory diseases (asthma and COPD), and immuno-oncology (melanoma, NSCLC, AML, ALL, multiple myeloma). Eight pharmaceutical companies became users or previous version of the platform. IRT was significantly updated during last year including significant improvement of MDSC description, description of immunological synapses with various co-stimulatory and co-inhibitory receptors, etc.
“IRT creates a unique opportunity for QSP modelers: instead of spending time on early stages of model development such as collection of experimental data, derivation of equations, identification of parameters against in vitro data, one can just use IRT and select required reactions and species, download the model with selected elements and use it as a basis of model of particular disease. Thus, IRT allows users to reduce the model development time by weeks or even months,” said Oleg Demin Jr, IRT project leader.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit http://insysbio.com.
| ← | May 2021 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
1.
19 May 2021 16:52
InSysBio to upgrade its SbmlViewer application
[Moscow – 19.05.2021] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches the new version (0.3.0) of its SbmlViewer open project. Generally, SbmlViewer is a tool for fast and easy reading and transformation of biological models written in SBML format.
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 May 2021 17:38
InSysBio to take part in SMB 2021
InSysBio announces its participation in Society of Mathematical Biology Annual Meeting (SMB 2021) which is to be held virtually this year June 13-17, 2021. InSysBio team is going to present 4 posters and Oleg Demin Jr is going to give a presentation "Implementation of variability or uncertainty in parameter values to validate QSP models." and Ivan Borisov is going to give a talk "Constrained Optimization Approach to Predictability Analysis in Bio-Mathematical Modeling."
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
